Innovative Biopharma Firms Rush to File for Hong Kong IPOs Amid Soaring Financing Momentum

　　【Pharmaceutical Network Industry DynamicsOn October 8, Eccogene submitted an application for listing on the Main Board of the Hong Kong Stock Exchange, adding momentum to the biopharmaceutical IPO market in Hong Kong this golden autumn. Since late September, several pharmaceutical companies including IMPACT Therapeutics, Sirius Therapeutics, and Betta Pharmaceuticals have successively disclosed their filing information, making Hong Kong once again a core financing hub for innovative pharmaceutical enterprises.
 

On October 8, Eccogene Inc. submitted an application for listing on the Main Board of the Hong Kong Stock Exchange. The prospectus shows that Eccogene is a global biotechnology company in the clinical stage, dedicated to exploring and developing a new generation of oral small molecule drugs to address significant unmet medical needs in the field of cardiovascular metabolic diseases and inflammatory diseases worldwide. Relying on its proprietary TRANDD platform, the company’s product pipeline is designed for both monotherapy and combination therapies, aiming to achieve effective results in weight management (obesity/overweight), metabolic associated steatohepatitis ("MASH"), osteoarthritis ("OA") pain, and other cardiovascular metabolic diseases.
 

The company has developed an oral small molecule GLP-1 receptor agonist ("GLP-1RA") ECC5004, which can be used as a monotherapy and is also the company's core therapy. It can be combined with other oral medications. The oral liver-targeted thyroid hormone receptor β ("THR-β") full agonist ECC4703 has the potential to become a liver-targeted selective THR-β full agonist for MASH treatment and weight management. ECC0509, an oral small molecule inhibitor of semicarbazide-sensitive amine oxidase ("SSAO") (also known as vascular adhesion protein-1 ("VAP-1")), can be used in combination with GLP-1 receptor agonists to fully exploit its application value.
 

In addition, IMPACT Therapeutics officially submitted its prospectus to the Hong Kong Stock Exchange on September 26. According to the data, IMPACT Therapeutics is committed to the research and development of targeted anti-cancer drugs with independent intellectual property rights. The core of its R&D pipeline is a PARP inhibitor named Senaparib (IMP4297). This drug was officially approved in January 2025 for first-line maintenance treatment of "entire population" ovarian cancer in China and has begun commercialization, marking a key "self-sustaining" turning point for the company. The subsequent R&D pipeline also includes ATR inhibitors, WEE1 inhibitors, ATM inhibitors, etc.
 

Sirius Therapeutics Submits Listing Application to HKEX on September 28. Data shows that Sirius Therapeutics is a global clinical-stage biotechnology company dedicated to developing siRNA therapies. siRNA therapies address disease mechanisms at the nucleic acid level and can target "undruggable" proteins that are difficult to reach with traditional technologies. siRNA therapies bring a paradigm shift to chronic disease management, offering advantages such as longer durability, higher compliance, good safety, and lower drug interactions. Data indicates that the siRNA therapy market has broad prospects, expected to grow from $2.4 billion in 2024 to $50.3 billion in 2040, with an annual compound growth rate of 20.9%.
 

Betta Pharmaceuticals submitted its listing application to the Main Board of the Hong Kong Stock Exchange on September 29. Data shows that by combining independent innovation with strategic cooperation, Betta Pharmaceuticals has successfully launched eight innovative targeted cancer therapy drugs and biosimilars, forming a diversified product pipeline. The company has established a multimodal discovery engine, integrating four proprietary technology platforms, including an advanced small molecule targeted drug platform, GlueOnX (molecular glue platform), DegradoX (Protein Degradation Targeting Chimera (PROTAC) degrader platform), and AlbuVive (albumin therapy platform), to advance innovative and historically "undruggable" targets.
 

Moreover, on September 15, Hangzhou New Element Pharmaceuticals and Shanghai Ark Biopharmaceuticals filed their documents simultaneously, focusing on metabolic diseases, respiratory system, and pediatric diseases respectively. New Element Pharmaceuticals' ABP-671 has achieved a breakthrough in uric acid reduction, while Ark Biopharmaceuticals' Ziresovir is the first RSV treatment drug at the NDA stage, both demonstrating differentiated competitive advantages.
 

The surge of pharmaceutical companies going public in Hong Kong is supported by the dual advantages of the Hong Kong stock market system and its market environment. The Chapter 18A rules introduced in 2018 allow unprofitable biotech companies to be listed, and the newly added "Tech Track" in May 2025 further optimizes the application process, supporting confidential filings, thereby lowering the financing threshold for innovative pharmaceutical companies.
 

For enterprises that have filed for listing, going public in Hong Kong is not only a source of capital replenishment but also a springboard for globalization. IMPACT Therapeutics is advancing its application in the European market, while Betta Pharmaceuticals is planning its overseas expansion, both attempting to leverage the Hong Kong stock platform to connect with international capital and clinical resources. As industry insiders have noted, this wave of listings represents not only the concentrated release of years of R&D accumulation but also an essential step for China's innovative pharmaceutical companies as they enter global competition.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.